Artivion price target raised to $45 from $32 at Needham

Needham analyst Mike Matson raised the firm’s price target on Artivion (AORT) to $45 from $32 and keeps a Buy rating on the shares. The company’s constant currency revenue growth improved to 14.6% in Q2 from 3.6% in Q1, driven by strong On-X and stent graft growth, the analyst tells investors in a research note. Artivion is also making further progress with its pipeline, including NEXUS and Arcevo, the firm added.